Evidence suggests that psilocybin-assisted therapy for those who have not responded to standard interventions may be beneficial.
|Articles|April 12, 2020
- Pharmacy Careers Spring 2020
- Volume 14
- Issue 1
Pharmacy Careers Digital Edition (Spring 2020)
Advertisement
Articles in this issue
over 6 years ago
YouTube Can Change Public Perception of Pharmacistsover 6 years ago
Student Success Starts with Self-Awarenessover 6 years ago
Advocacy: An Essential Skill for the Modern Pharmacy Studentover 6 years ago
Perserverance After Match Day Uncertainty Leads to Opportunityover 6 years ago
Student Pharmacist Leaders Discuss the Future of Pharmacyover 6 years ago
Residency Programs Are Competitive, but Students Can Stand Outover 6 years ago
Handling Professional Ghosting in PharmacyAdvertisement
Related to this article
Investigational antiamyloid monoclonal antibodies may offer a novel pathway to disease reversal.
Increasingly, pharmacists are leading the obesity management team.
A panel of cardiology pharmacists discussed the diagnostic red flags, evolving treatment landscape, and expanding pharmacist role central to identifying and managing ATTR-CM.
Weight-based norepinephrine dosing did not improve time to goal MAP, and median dose was similar compared with non–weight-based dosing in patients with septic shock.
The panelists emphasized that selecting a therapy is only one step toward improving outcomes for patients with heart failure.
Pharmacists can educate patients about staying up to date on immunizations and discuss fall prevention strategies.
Pharmacists describe their experiences using DEA certificates for controlled substance prescribing in different practice settings, as well as barriers and opportunities for future expansion.
Advertisement
Advertisement
Trending on Pharmacy Times
1
After 180 Years, Multiple Myeloma Gets a Definition of Cure
2
FDA Approves Belzutifan Plus Lenvatinib for Advanced Renal Cell Carcinoma After Immunotherapy
3
Severe Asthma's Effects May Extend Beyond the Lungs, Brain Imaging Study Suggests
4
FDA Approves Insulin Efsitora, Once-Weekly Basal Insulin Injection for Adults With T2D
5